English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
  Prognostic impact of [18F]fluorothymidine and [18F]fluoro-D-glucose baseline uptakes in patients with lung cancer treated first-line with Erlotinib

Scheffler, M., Zander, T., Nogova, L., Kobe, C., Kahraman, D., Dietlein, F., et al. (2013). Prognostic impact of [18F]fluorothymidine and [18F]fluoro-D-glucose baseline uptakes in patients with lung cancer treated first-line with Erlotinib. PLoS ONE, 8(1): e53081. doi:10.1371/journal.pone.0053081.

Item is

Files

show Files

Locators

show

Creators

show
hide
 Creators:
Scheffler, Matthias1, Author
Zander, Thomas2, Author           
Nogova, Lucia1, Author
Kobe, Carsten1, Author
Kahraman, Deniz1, Author
Dietlein, Felix3, Author           
Papachristou, Irini1, Author
Heukamp, Lukas1, Author
Büttner, Reinhard1, Author
Boellaard, Ronald1, Author
Lammertsma, Adriaan A.1, Author
Querings, Silvia3, Author           
Stoelben, Erich1, Author
Engel-Riedel, Walburga1, Author
Neumaier, Bernd4, Author           
Wolf, Johanna1, Author
Affiliations:
1a Department I for Internal Medicine, University Hospital of Cologne, Cologne, Germany b Center for Integrated Oncology Köln Bonn, Cologne, Germany c Clinic for Nuclear Medicine, University Hospital of Cologne, Cologne, Germany d Institute of Pathology, University Hospital Cologne, Cologne, Germany e Department of Nuclear Medicine and PET Research, VU University Medical Center Amsterdam, Amsterdam, Netherlands f Lung Clinic Merheim, Hospital of Cologne, Cologne, Germany, ou_persistent22              
2Klinisches PET, Neurologische Abteilung, Max-Planck-Institut für neurologische Forschung, Managing Director: D. Yves von Cramon, Max Planck Institute for Metabolism Research, Managing Director: Jens Brüning, Max Planck Society, ou_2149663              
3Funktionelle Krebsgenomforschung, Junior Research Groups, Max-Planck-Institut für neurologische Forschung, Managing Director: D. Yves von Cramon, Max Planck Institute for Metabolism Research, Managing Director: Jens Brüning, Max Planck Society, ou_2149656              
4Radiochemistry, Scientific Services and Development, Max Planck Institute for Metabolism Research, Managing Director: Jens Brüning, Max Planck Society, ou_2149672              

Content

show
hide
Free keywords: -
 Abstract: © 2013 Scheffler et al.

Details

show
hide
Language(s): eng - English
 Dates: 2013
 Publication Status: Published in print
 Pages: -
 Publishing info: -
 Table of Contents: -
 Rev. Type: Peer
 Identifiers: eDoc: 631095
DOI: 10.1371/journal.pone.0053081
 Degree: -

Event

show

Legal Case

show

Project information

show

Source 1

show
hide
Title: PLoS ONE
Source Genre: Journal
 Creator(s):
Affiliations:
Publ. Info: -
Pages: - Volume / Issue: 8 (1) Sequence Number: e53081 Start / End Page: - Identifier: ISSN: 19326203